Ardent Health (ARDT) Stephens Annual Investment Conference summary

Strategic growth and capital deployment

• Announced a $50 million share repurchase program, reflecting strong liquidity and modest leverage, with over $800 million available.

• Growth strategy centers on expanding outpatient footprint, opportunistic M&A in core and new markets, and margin expansion through impact initiatives.

• Added 27 urgent care centers in the past year and a half, serving as a key entry point for new patients and supporting downstream services.

• Prioritizing de novo ASC builds over acquisitions due to favorable economics and strong physician partnerships.

• Joint venture model remains central, with disciplined M&A focused on midsize urban markets with positive growth.

Financial performance and margin initiatives

• $40 million in annualized savings achieved, mainly from labor optimization and contract renegotiation, with further opportunities in revenue integrity, supply chain, and productivity.

• Margin expansion targeted to reach mid-teens over time, despite persistent headwinds from professional fees and payer denials.

• Outpatient and inpatient admissions are growing, with admissions up over 6% year-to-date and outpatient growth at 2.9% in Q3.

• Impact initiatives include technology investments, such as ambient listening for documentation, expected to improve productivity and reduce clinician burnout.

• No rural health benefit included in current savings; any future upside from state programs would be incremental.

Industry headwinds and payer dynamics

• Facing industry-wide challenges from payer denials, especially in managed products and exchanges, with denials nearly double those in traditional plans.

• Recent renegotiation of a major contract in Texas improved rates and cash flow mechanisms, shifting cash control to the provider.

• Professional fee pressures peaked in 2023, especially in radiology and anesthesiology, with moderation expected in 2024 and beyond.

• Exchange and managed product volumes are growing, but reimbursement rates are closer to Medicare than traditional commercial, impacting yield.

• Ongoing efforts to optimize payer mix and contract terms to improve yield and reduce denial rates.